Mr Alastair D Lamb, MA(Oxon), MBChB, PhD(Cantab), FRCS(Urol)
is a Cancer Research UK Clinician Scientist, Senior Fellow in Robotic Surgery and Honorary Consultant Urologist at the Nuffield Department of Surgery, University of Oxford and Oxford University Hospitals NHS Foundation Trust, UK.
My clinical focus is to deliver excellent and timely prostate cancer care to men referred to our team from the Oxford regional area, focussing on state-of-the-art diagnostics with multiparametric MRI and targeted transperineal biopsies, followed by robotic-radical prostatectomy (RARP) or indeed active surveillance where appropriate. I have a particular interest in pushing the boundaries of minimal access surgery (MIS), for example to performing cytoreductive radical prostectomy in locally advanced or metastatic disease and RARP in fit, older men where such approaches are deemed safe and evidence-based.
My research goal is to provide a robust molecular platform for accurate decision-making in early stage prostate cancer.
In this blog for a non-medical audience, Alastair Lamb and Altan Omer look at the evidence for use of PDE5 inhibitors (Viagra, Cialis & Levitra) for penile rehabilitation after prostate cancer surgery.